nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—Differentiation Pathway—ALK—peripheral nervous system neoplasm	0.00812	0.0491	CbGpPWpGaD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	0.00475	0.0287	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	0.0046	0.0278	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.00418	0.0253	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00396	0.0239	CbGpPWpGaD
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.00358	0.0216	CbGpPWpGaD
Gliclazide—ABCC8—ABC-family proteins mediated transport—ABCB1—peripheral nervous system neoplasm	0.00296	0.0179	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BARD1—peripheral nervous system neoplasm	0.00262	0.0158	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—NTRK2—peripheral nervous system neoplasm	0.00251	0.0152	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—HGF—peripheral nervous system neoplasm	0.00241	0.0146	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—PTPN11—peripheral nervous system neoplasm	0.00227	0.0137	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.00211	0.0127	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—HGF—peripheral nervous system neoplasm	0.00208	0.0126	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—NTRK1—peripheral nervous system neoplasm	0.00205	0.0124	CbGpPWpGaD
Gliclazide—ABCC8—Regulation of insulin secretion—SLC2A1—peripheral nervous system neoplasm	0.00204	0.0123	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—PTPN11—peripheral nervous system neoplasm	0.002	0.0121	CbGpPWpGaD
Gliclazide—KCNJ11—Regulation of insulin secretion—SLC2A1—peripheral nervous system neoplasm	0.00198	0.0119	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—EED—peripheral nervous system neoplasm	0.00197	0.0119	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—MET—peripheral nervous system neoplasm	0.0019	0.0115	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—BDNF—peripheral nervous system neoplasm	0.00188	0.0113	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—CDKN2A—peripheral nervous system neoplasm	0.00178	0.0108	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00177	0.0107	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—ERBB2—peripheral nervous system neoplasm	0.0017	0.0103	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—ABCB1—peripheral nervous system neoplasm	0.00166	0.01	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—KNG1—peripheral nervous system neoplasm	0.00166	0.01	CbGpPWpGaD
Gliclazide—ABCC8—Regulation of insulin secretion—GNAS—peripheral nervous system neoplasm	0.00164	0.00991	CbGpPWpGaD
Gliclazide—VEGFA—Heart Development—PTPN11—peripheral nervous system neoplasm	0.00163	0.00984	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.00162	0.00976	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—SLC2A1—peripheral nervous system neoplasm	0.0016	0.00968	CbGpPWpGaD
Gliclazide—KCNJ11—Regulation of insulin secretion—GNAS—peripheral nervous system neoplasm	0.00159	0.00961	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—KNG1—peripheral nervous system neoplasm	0.00158	0.00956	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—SUZ12—peripheral nervous system neoplasm	0.00157	0.0095	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—SLC2A1—peripheral nervous system neoplasm	0.00155	0.00939	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	0.00153	0.00924	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—CNTN6—peripheral nervous system neoplasm	0.00153	0.00923	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—ABCB1—peripheral nervous system neoplasm	0.00144	0.0087	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—HGF—peripheral nervous system neoplasm	0.00138	0.00836	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—HGF—peripheral nervous system neoplasm	0.00132	0.00797	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—PTPN11—peripheral nervous system neoplasm	0.00131	0.00789	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—GNAS—peripheral nervous system neoplasm	0.00129	0.00779	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—GNAS—peripheral nervous system neoplasm	0.00125	0.00755	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—PTPN11—peripheral nervous system neoplasm	0.00122	0.00738	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—MYC—peripheral nervous system neoplasm	0.00121	0.00729	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—NRAS—peripheral nervous system neoplasm	0.0012	0.00727	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.00119	0.0072	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.00117	0.00706	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—PTPN11—peripheral nervous system neoplasm	0.00115	0.00695	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.00114	0.00688	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CNTN6—peripheral nervous system neoplasm	0.00109	0.00659	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.00105	0.00631	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.00104	0.0063	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—AKT1—peripheral nervous system neoplasm	0.00103	0.00621	CbGpPWpGaD
Gliclazide—VEGFA—S1P3 pathway—AKT1—peripheral nervous system neoplasm	0.000995	0.00601	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—TP53—peripheral nervous system neoplasm	0.000992	0.00599	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—HRAS—peripheral nervous system neoplasm	0.000949	0.00573	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000946	0.00571	CbGpPWpGaD
Gliclazide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000941	0.00568	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—AKT1—peripheral nervous system neoplasm	0.000884	0.00534	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—HRAS—peripheral nervous system neoplasm	0.000881	0.00532	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000881	0.00532	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000866	0.00523	CbGpPWpGaD
Gliclazide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000858	0.00518	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—CASP3—peripheral nervous system neoplasm	0.000856	0.00517	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00085	0.00513	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000817	0.00493	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—PTPN11—peripheral nervous system neoplasm	0.0008	0.00483	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.00079	0.00477	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—NRAS—peripheral nervous system neoplasm	0.000786	0.00474	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000769	0.00464	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000763	0.00461	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—PTPN11—peripheral nervous system neoplasm	0.000756	0.00456	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—NCAM1—peripheral nervous system neoplasm	0.000746	0.00451	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000745	0.0045	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—BCHE—peripheral nervous system neoplasm	0.00074	0.00447	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00074	0.00447	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000737	0.00445	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CASP3—peripheral nervous system neoplasm	0.000732	0.00442	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000723	0.00437	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000711	0.00429	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HGF—peripheral nervous system neoplasm	0.000693	0.00419	CbGpPWpGaD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	0.000693	0.00418	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000692	0.00418	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IFNB1—peripheral nervous system neoplasm	0.00069	0.00417	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	0.000672	0.00406	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000614	0.00371	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—KNG1—peripheral nervous system neoplasm	0.000587	0.00354	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—HRAS—peripheral nervous system neoplasm	0.000575	0.00347	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—KNG1—peripheral nervous system neoplasm	0.000559	0.00337	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000549	0.00331	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—MET—peripheral nervous system neoplasm	0.000547	0.0033	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.000533	0.00322	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000525	0.00317	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000519	0.00314	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000503	0.00304	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—HGF—peripheral nervous system neoplasm	0.000489	0.00295	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—peripheral nervous system neoplasm	0.000481	0.00291	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—AKT1—peripheral nervous system neoplasm	0.000475	0.00287	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—AKT1—peripheral nervous system neoplasm	0.000469	0.00283	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—HGF—peripheral nervous system neoplasm	0.000466	0.00281	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000463	0.0028	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	0.000458	0.00276	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—NRAS—peripheral nervous system neoplasm	0.000454	0.00274	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—peripheral nervous system neoplasm	0.000447	0.0027	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000436	0.00263	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000425	0.00256	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.00041	0.00248	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—ERBB2—peripheral nervous system neoplasm	0.0004	0.00241	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000398	0.0024	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000391	0.00236	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—peripheral nervous system neoplasm	0.000391	0.00236	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KNG1—peripheral nervous system neoplasm	0.00038	0.0023	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000376	0.00227	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GNS—peripheral nervous system neoplasm	0.000375	0.00227	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GNS—peripheral nervous system neoplasm	0.000364	0.0022	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000361	0.00218	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NME1—peripheral nervous system neoplasm	0.00036	0.00217	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MET—peripheral nervous system neoplasm	0.000357	0.00215	CbGpPWpGaD
Gliclazide—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000352	0.000422	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	0.000352	0.00213	CbGpPWpGaD
Gliclazide—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000352	0.000422	CcSEcCtD
Gliclazide—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000351	0.000421	CcSEcCtD
Gliclazide—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000351	0.000421	CcSEcCtD
Gliclazide—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000351	0.000421	CcSEcCtD
Gliclazide—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.00035	0.000419	CcSEcCtD
Gliclazide—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000349	0.000419	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—NME1—peripheral nervous system neoplasm	0.000349	0.00211	CbGpPWpGaD
Gliclazide—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000348	0.000417	CcSEcCtD
Gliclazide—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000348	0.000417	CcSEcCtD
Gliclazide—ABCC8—Metabolism—COX2—peripheral nervous system neoplasm	0.000346	0.00209	CbGpPWpGaD
Gliclazide—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000345	0.000414	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000342	0.00041	CcSEcCtD
Gliclazide—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000341	0.000409	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.00034	0.00206	CbGpPWpGaD
Gliclazide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00034	0.000407	CcSEcCtD
Gliclazide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000339	0.000407	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000339	0.000406	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000337	0.00204	CbGpPWpGaD
Gliclazide—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000337	0.000403	CcSEcCtD
Gliclazide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000336	0.000403	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—COX2—peripheral nervous system neoplasm	0.000336	0.00203	CbGpPWpGaD
Gliclazide—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000336	0.000403	CcSEcCtD
Gliclazide—Pain—Cisplatin—peripheral nervous system neoplasm	0.000336	0.000402	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	0.000332	0.00201	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000332	0.00201	CbGpPWpGaD
Gliclazide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000331	0.000396	CcSEcCtD
Gliclazide—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.000396	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.00033	0.00199	CbGpPWpGaD
Gliclazide—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000329	0.000395	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000328	0.000393	CcSEcCtD
Gliclazide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000327	0.000392	CcSEcCtD
Gliclazide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000326	0.000391	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000324	0.000388	CcSEcCtD
Gliclazide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000323	0.000388	CcSEcCtD
Gliclazide—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000323	0.000387	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000387	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	0.000321	0.00194	CbGpPWpGaD
Gliclazide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000321	0.000384	CcSEcCtD
Gliclazide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00032	0.000383	CcSEcCtD
Gliclazide—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00032	0.000383	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00032	0.000383	CcSEcCtD
Gliclazide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000319	0.000382	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000381	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—HGF—peripheral nervous system neoplasm	0.000317	0.00191	CbGpPWpGaD
Gliclazide—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000379	CcSEcCtD
Gliclazide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000316	0.000379	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000315	0.000378	CcSEcCtD
Gliclazide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000315	0.000378	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000315	0.0019	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000313	0.000376	CcSEcCtD
Gliclazide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000313	0.000375	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000373	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	0.000311	0.00188	CbGpPWpGaD
Gliclazide—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000311	0.000372	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00031	0.000372	CcSEcCtD
Gliclazide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00031	0.000372	CcSEcCtD
Gliclazide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00031	0.000372	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000371	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000309	0.00187	CbGpPWpGaD
Gliclazide—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000308	0.000369	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000308	0.00186	CbGpPWpGaD
Gliclazide—Pain—Etoposide—peripheral nervous system neoplasm	0.000308	0.000369	CcSEcCtD
Gliclazide—Constipation—Etoposide—peripheral nervous system neoplasm	0.000308	0.000369	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000368	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000368	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.000365	CcSEcCtD
Gliclazide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000305	0.000365	CcSEcCtD
Gliclazide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000304	0.000364	CcSEcCtD
Gliclazide—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000303	0.000363	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000359	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000299	0.000358	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000358	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000357	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000297	0.000355	CcSEcCtD
Gliclazide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000296	0.000355	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000296	0.000355	CcSEcCtD
Gliclazide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000295	0.000354	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000295	0.000354	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.000353	CcSEcCtD
Gliclazide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000294	0.000352	CcSEcCtD
Gliclazide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000294	0.000352	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.000293	0.00177	CbGpPWpGaD
Gliclazide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000293	0.000351	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000351	CcSEcCtD
Gliclazide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00029	0.000348	CcSEcCtD
Gliclazide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00029	0.000348	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.000348	CcSEcCtD
Gliclazide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000289	0.000347	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000346	CcSEcCtD
Gliclazide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000289	0.000346	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000345	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000287	0.00173	CbGpPWpGaD
Gliclazide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000344	CcSEcCtD
Gliclazide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000286	0.000342	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000285	0.000342	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000341	CcSEcCtD
Gliclazide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000284	0.000341	CcSEcCtD
Gliclazide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000284	0.000341	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000341	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000341	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000284	0.00034	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000282	0.000338	CcSEcCtD
Gliclazide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000282	0.000338	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000282	0.0017	CbGpPWpGaD
Gliclazide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000282	0.000338	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000282	0.000338	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000336	CcSEcCtD
Gliclazide—Rash—Vincristine—peripheral nervous system neoplasm	0.00028	0.000335	CcSEcCtD
Gliclazide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00028	0.000335	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.00028	0.00169	CbGpPWpGaD
Gliclazide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.00028	0.000335	CcSEcCtD
Gliclazide—Headache—Vincristine—peripheral nervous system neoplasm	0.000278	0.000333	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000332	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000331	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000275	0.00166	CbGpPWpGaD
Gliclazide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.000329	CcSEcCtD
Gliclazide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000274	0.000328	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000328	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000327	CcSEcCtD
Gliclazide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000269	0.000322	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000322	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.00032	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000265	0.000318	CcSEcCtD
Gliclazide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000265	0.000318	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000265	0.000317	CcSEcCtD
Gliclazide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000264	0.000316	CcSEcCtD
Gliclazide—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000316	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000315	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000315	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000313	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—ERBB2—peripheral nervous system neoplasm	0.000261	0.00157	CbGpPWpGaD
Gliclazide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000312	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.00026	0.00157	CbGpPWpGaD
Gliclazide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000259	0.00031	CcSEcCtD
Gliclazide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000258	0.000309	CcSEcCtD
Gliclazide—Chills—Epirubicin—peripheral nervous system neoplasm	0.000255	0.000305	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MET—peripheral nervous system neoplasm	0.000255	0.00154	CbGpPWpGaD
Gliclazide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000254	0.000305	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000253	0.000304	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000303	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00025	0.000299	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000249	0.000298	CcSEcCtD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000248	0.0015	CbGpPWpGaD
Gliclazide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000298	CcSEcCtD
Gliclazide—ALB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000248	0.0015	CbGpPWpGaD
Gliclazide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000248	0.000297	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000247	0.000296	CcSEcCtD
Gliclazide—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000296	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000296	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000246	0.000295	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.000294	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.000293	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000292	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000243	0.000292	CcSEcCtD
Gliclazide—Tension—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000291	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000288	CcSEcCtD
Gliclazide—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000239	0.000286	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000238	0.00144	CbGpPWpGaD
Gliclazide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000238	0.000285	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000236	0.00143	CbGpPWpGaD
Gliclazide—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.000282	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—PTPN11—peripheral nervous system neoplasm	0.000235	0.00142	CbGpPWpGaD
Gliclazide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000281	CcSEcCtD
Gliclazide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000233	0.000279	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000232	0.0014	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000231	0.00139	CbGpPWpGaD
Gliclazide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.00023	0.000276	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000275	CcSEcCtD
Gliclazide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000229	0.000274	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000274	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000274	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000274	CcSEcCtD
Gliclazide—ABCC8—Metabolism—ENO2—peripheral nervous system neoplasm	0.000227	0.00137	CbGpPWpGaD
Gliclazide—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000272	CcSEcCtD
Gliclazide—Rash—Etoposide—peripheral nervous system neoplasm	0.000227	0.000272	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000227	0.000272	CcSEcCtD
Gliclazide—Headache—Etoposide—peripheral nervous system neoplasm	0.000225	0.00027	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.00027	CcSEcCtD
Gliclazide—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000269	CcSEcCtD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	0.000223	0.00135	CbGpPWpGaD
Gliclazide—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000223	0.000267	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000222	0.00134	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—peripheral nervous system neoplasm	0.000222	0.00134	CbGpPWpGaD
Gliclazide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000266	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000265	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000221	0.000265	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—ENO2—peripheral nervous system neoplasm	0.000221	0.00133	CbGpPWpGaD
Gliclazide—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000218	0.000262	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000217	0.00131	CbGpPWpGaD
Gliclazide—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000217	0.00026	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000217	0.00131	CbGpPWpGaD
Gliclazide—Cough—Epirubicin—peripheral nervous system neoplasm	0.000216	0.000258	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000256	CcSEcCtD
Gliclazide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000214	0.000256	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000256	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000254	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000253	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000252	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000252	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000252	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000252	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000251	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000209	0.00025	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000249	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.000247	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000246	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000245	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000203	0.000244	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000203	0.00122	CbGpPWpGaD
Gliclazide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000242	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.000241	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000201	0.00121	CbGpPWpGaD
Gliclazide—Infection—Epirubicin—peripheral nervous system neoplasm	0.0002	0.00024	CcSEcCtD
Gliclazide—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000239	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—NRAS—peripheral nervous system neoplasm	0.000198	0.0012	CbGpPWpGaD
Gliclazide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000237	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000237	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000237	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000236	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000236	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—AKT1—peripheral nervous system neoplasm	0.000196	0.00119	CbGpPWpGaD
Gliclazide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000235	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000196	0.00118	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000234	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000233	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000233	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000233	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000232	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000232	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.00023	CcSEcCtD
Gliclazide—ABCC8—Metabolism—BCHE—peripheral nervous system neoplasm	0.000192	0.00116	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	0.000191	0.00115	CbGpPWpGaD
Gliclazide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000228	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000226	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000188	0.000225	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—BCHE—peripheral nervous system neoplasm	0.000186	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—ERBB2—peripheral nervous system neoplasm	0.000186	0.00112	CbGpPWpGaD
Gliclazide—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000222	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000184	0.00022	CcSEcCtD
Gliclazide—ABCC8—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000183	0.00111	CbGpPWpGaD
Gliclazide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000219	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000219	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000219	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000218	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000217	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000217	CcSEcCtD
Gliclazide—ABCC8—Metabolism—TH—peripheral nervous system neoplasm	0.000181	0.00109	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000216	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.00018	0.000215	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000215	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—HRAS—peripheral nervous system neoplasm	0.000179	0.00108	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—peripheral nervous system neoplasm	0.000179	0.00108	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000178	0.00107	CbGpPWpGaD
Gliclazide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000213	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—TH—peripheral nervous system neoplasm	0.000175	0.00106	CbGpPWpGaD
Gliclazide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000209	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	0.000174	0.00105	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000209	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000208	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—HRAS—peripheral nervous system neoplasm	0.000174	0.00105	CbGpPWpGaD
Gliclazide—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000207	CcSEcCtD
Gliclazide—Pain—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000207	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000204	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000202	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000201	CcSEcCtD
Gliclazide—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000167	0.00101	CbGpPWpGaD
Gliclazide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000199	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000199	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000199	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000198	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000197	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000193	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000193	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000192	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000191	CcSEcCtD
Gliclazide—Pain—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000191	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000191	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000191	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000184	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000183	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000151	0.00091	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00015	0.000907	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000178	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000178	CcSEcCtD
Gliclazide—ABCC8—Metabolism—GNAS—peripheral nervous system neoplasm	0.000147	0.000891	CbGpPWpGaD
Gliclazide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000177	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000177	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—HRAS—peripheral nervous system neoplasm	0.000145	0.000876	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000145	0.000874	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000145	0.000874	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000173	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—GNAS—peripheral nervous system neoplasm	0.000143	0.000864	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000171	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—NRAS—peripheral nervous system neoplasm	0.000142	0.000855	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ABCB1—peripheral nervous system neoplasm	0.00014	0.000847	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000139	0.00084	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—peripheral nervous system neoplasm	0.000139	0.000839	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000165	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000165	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000137	0.000827	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000134	0.00081	CbGpPWpGaD
Gliclazide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.00016	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000133	0.00016	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000158	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000129	0.000778	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000154	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000153	CcSEcCtD
Gliclazide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000152	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000152	CcSEcCtD
Gliclazide—Headache—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000151	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000126	0.000762	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000125	0.000754	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000148	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000123	0.000742	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNS—peripheral nervous system neoplasm	0.000121	0.000731	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000144	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000142	CcSEcCtD
Gliclazide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000141	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000141	CcSEcCtD
Gliclazide—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000117	0.000708	CbGpPWpGaD
Gliclazide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.00014	CcSEcCtD
Gliclazide—ALB—Metabolism—NME1—peripheral nervous system neoplasm	0.000116	0.000701	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000114	0.000688	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000113	0.00068	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	0.000112	0.000675	CbGpPWpGaD
Gliclazide—ALB—Metabolism—COX2—peripheral nervous system neoplasm	0.000112	0.000674	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000133	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	0.000109	0.000656	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—peripheral nervous system neoplasm	0.000106	0.000642	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	0.000104	0.000629	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—peripheral nervous system neoplasm	0.000104	0.000625	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000102	0.000614	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000102	0.000613	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	0.0001	0.000605	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	9.96e-05	0.000602	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	9.91e-05	0.000598	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	9.5e-05	0.000574	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—peripheral nervous system neoplasm	9.14e-05	0.000552	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	9.14e-05	0.000552	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—peripheral nervous system neoplasm	8.97e-05	0.000542	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	8.15e-05	0.000492	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.83e-05	0.000473	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	7.33e-05	0.000443	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	6.58e-05	0.000398	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	6.2e-05	0.000374	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.19e-05	0.000374	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	6.14e-05	0.000371	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	6e-05	0.000362	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.91e-05	0.000357	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TH—peripheral nervous system neoplasm	5.83e-05	0.000352	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.62e-05	0.000339	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	5.56e-05	0.000336	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.31e-05	0.00032	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	5.23e-05	0.000316	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	5.07e-05	0.000306	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	4.9e-05	0.000296	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.84e-05	0.000292	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	4.77e-05	0.000288	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	4.76e-05	0.000287	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.71e-05	0.000284	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	4.67e-05	0.000282	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.39e-05	0.000265	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	4.27e-05	0.000258	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	4.19e-05	0.000253	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—peripheral nervous system neoplasm	3.98e-05	0.00024	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	3.89e-05	0.000235	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—peripheral nervous system neoplasm	3.86e-05	0.000233	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	3.82e-05	0.000231	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	3.75e-05	0.000226	CbGpPWpGaD
Gliclazide—Chlorpropamide—ABCB1—peripheral nervous system neoplasm	3.7e-05	0.597	CrCbGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.6e-05	0.000217	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	3.59e-05	0.000217	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.44e-05	0.000208	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	3.17e-05	0.000191	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.04e-05	0.000184	CbGpPWpGaD
Gliclazide—Glyburide—ABCB1—peripheral nervous system neoplasm	2.5e-05	0.403	CrCbGaD
Gliclazide—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	1.28e-05	7.75e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.15e-05	6.96e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.05e-05	6.34e-05	CbGpPWpGaD
